Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vigil Neuroscience, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants who have documentation of a gene mutation in the CSF1R gene
Participants fulfill both (Parts A and B) of the following criteria:
1. The participant has more than 2 findings of clinical signs or symptoms in the following categories:
1. Cognitive impairment or psychiatric problem
2. Pyramidal signs on neurological examination
3. Extrapyramidal signs, such as rigidity.
4. Epilepsy
2. MRI findings consistent with ALSP, specifically, bilateral cerebral white matter lesions with or without thinning of the corpus callosum, on the Screening MRI.
The participant must have a study partner (i.e., caregiver, family member, friend, etc.) who, in the investigator's judgment, has frequent and sufficient contact with the subject so as to be able to provide accurate information about the participant's health and cognitive and functional abilities. The study partner must be willing to sign a study partner ICF.
You may not be if
The participant has any neurological disease that poses a risk to the participant or can produce cognitive, motor, or behavioral impairment similar to ALSP, including, but not limited to, brain tumor, hydrocephalus, Alzheimer's disease, frontotemporal dementia (FTD), ALS, stroke, Huntington disease, multiple sclerosis, Parkinson's disease, and Down syndrome.
Participant with any condition or situation that, in the opinion of the investigator or sponsor medical personnel, may place the subject at significant risk, confound the study results, or interfere significantly with the participant's participation in the study.
Clareo Health | A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
